Search For "drugs controller general of india"
DCGI nods anti-COVID drug developed by DRDO for emergency use
Updated : 4 years, 10 months ago IST
New Delhi [India], May 8 (ANI): The Drugs Controller General of India (DCGI) has approved the emergency use of an anti-COVID drug - 2-deoxy-D-glucose (2-DG) - as an adjunct therapy in moderate to severe COVID-19 cases.
Read More
VINS Bioproducts gets DCGI nod to commence clinical trials for VINCOV-19
Updated : 4 years, 10 months ago IST
Hyderabad (Telangana) [India], April 26 (ANI): VINS Bioproducts on Monday received approval from the Drugs Controller General of India (DCGI) to commence the clinical trials for VINCOV-19, an antidote, and a cure against COVID-19, the Hyderabad based immunological company said.
Read More
DGCI approves emergency use of Zydus's Virafin in treating moderate COVID-
Updated : 4 years, 11 months ago IST
New Delhi [India], April 23 (ANI): Zydus Cadila received emergency use approval from the Drugs Controller General of India (DGCI) on Friday for the use of 'Virafin', Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults.
Read More
Zydus' Virafin gets emergency use approval for treating moderate COVID-19
Updated : 4 years, 11 months ago IST
New Delhi [India], April 23 (ANI): The Drugs Controller General of India (DGCI) has approved emergency use for Zydus Cadila's Pegylated Interferon alpha-2b, 'Virafin' for treating moderate COVID-19 infection in adults.
Read More
Zydus Cadila seeks DCGI nod for using its hepatitis drug for COVID-19 trea
Updated : 4 years, 11 months ago IST
New Delhi (India) [India], April 5 (ANI): Pharmaceutical Company Zydus Cadila on Monday informed that it has sought approval of the Drugs Controller General of India (DGCI) for using its hepatitis drug for the treatment of coronavirus.
Read More
SEC recommends authorisation to Covaxin without 'clinical trial mode'
Updated : 5 years ago IST
New Delhi [India], March 10 (ANI): The Subject expert committee (SEC) of Drugs Controller General of India (DCGI) on Wednesday recommended removing the "clinical trial mode" condition related to Bharat Biotech's Covaxin.
Read More
Dr Reddy's initiates process for emergency use authorisation of Sputnik V
Updated : 5 years ago IST
Hyderabad (Telangana) [India], Feb 19 (ANI): Dr Reddy's Laboratories said on Friday it has initiated the process with the Drugs Controller General of India (DCGI) for emergency use authorisation of human adenoviral vector-based platform vaccine candidate Sputnik V.
Read More
Pfizer showed no plans to generate safety data in Indian population for CO
Updated : 5 years, 1 month ago IST
New Delhi [India] February 5 (ANI): The subject expert panel of Drugs Controller General of India did not recommend granting emergency use authorisation to Pfizer's COVID-19 vaccine noting that the firm has not proposed plans to generate safety and immunogenicity data concerning Indian popu
Read More
Serum Institute seeks DCGI nod for clinical trials of COVID-19 vaccine COV
Updated : 5 years, 1 month ago IST
New Delhi [India], January 30 (ANI): Pharma giant Serum Institute of India (SII), whose Covishield vaccine has already received restricted emergency use approval by the Drugs Controller General of India (DCGI), has now sought permission to start clinical trials of 'COVOVAX', a COVID-19 vacci
Read More
There is no choice between vaccines, says Karnataka Health Minister over K
Updated : 5 years, 2 months ago IST
Bengaluru (Karnataka) [India], January 19 (ANI): After the Karnataka Association of Resident Doctors' objected to taking the Covaxin shot developed by Hyderabad-based Bharat Biotech and requested the government to use Covishield vaccine instead, Karnataka Health Minister Dr K Sudhakar on Tue
Read More
Sputnik V meets primary endpoint of safety in phase 2 clinical trial in In
Updated : 5 years, 2 months ago IST
Hyderabad (Telangana) [India], January 12 (ANI): Dr Reddy's Laboratories has said that independent Data and Safety Monitoring Board (DSMB) reviewed the safety data from phase two clinical trial of Russia's Covid-19 vaccine Sputnik V and recommended phase three recruitment along with continui
Read More
Bharat Biotech seeks DCGI's nod to conduct trials of nasal COVID-19 vaccin
Updated : 5 years, 2 months ago IST
New Delhi [India], January 8 (ANI): The Bharat Biotech International Limited has sent a proposal to the Drugs Controller General of India (DCGI) for conducting the phase 1 trials of a nasal vaccine against COVID-19, informed a government official on Friday.
Read More